within Pharmacolibrary.Drugs.ATC.H;

model H01AC06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.5466666666666666,
    adminDuration  = 600,
    adminMass      = 0.002,
    adminCount     = 1,
    Vd             = 0.0094,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Tesamorelin is a synthetic peptide analogue of human growth hormone-releasing factor (GRF/ GHRH) used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates the pituitary gland to increase the secretion of endogenous growth hormone (GH). Tesamorelin is approved by the FDA for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers (both sexes, aged 18â€“55 years) after subcutaneous administration.</p><h4>References</h4><ol><li>Carl Grunfeld, Argyris Dritselis, Peter Kirkpatrick,Tesamorelin.,Nature reviews. Drug discovery,2011<a href='https://pubmed.ncbi.nlm.nih.gov/21283099/'>https://pubmed.ncbi.nlm.nih.gov/21283099/</a></li><li>Sohita Dhillon,Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.,Drugs,2011<a href='https://pubmed.ncbi.nlm.nih.gov/21668043/'>https://pubmed.ncbi.nlm.nih.gov/21668043/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H01AC06;
